1st
A network of opportunities
The first edition of GAM dedicated to Medical Devices concluded on Friday October 27th , and we would like to thank all those who participated, offering valuable insights into trends, opportunities, and future scenarios for the industry.
When we began planning this conference, our goal was to provide a 360-degree exploration of the dynamics that characterize the scientific, regulatory, and commercial aspects, sharing the extensive know-how of Galileo Research with leading medical device manufacturers.
However, thanks to the participation of speakers with diverse expertise who fueled the debate through successful case studies, GAM has become an occasion for discussion and networking, bringing together the best talents in the industry.
Dorina Stanculescu Head of Communication & PR at InSilicoTrials, illustrated how in silico simulations can simplify the regulatory approval process for medical devices.
Dr. Testai Emanuela , Research Manager at the Istituto Superiore di Sanità, delved into the details of safety preclinical evaluation tests for substance-based devices.
Dr. Aldo Tomasi , Scientific Director of TPM, Tecnopark for Medicine, outlined updates and challenges related to recent provisions for the toxicological risk assessment of medical devices contained in the new ISO 10993-17.
Opportunities and support for manufacturing companies were also discussed. Dr. Andrea Pieri, Business Development Director and Valeska Sharon and Lola Frech BD – Medical Devices (Regulatory Affairs) at Pharma D&S, talked about consulting services, while Dr. Marco Focarelli , CEO of Synergy, discussed financing options.
The state of the industry was further complemented by a presentation from Dr. Silvia Trasciatti , Scientific Director of Galileo Research Srl , who introduced Galileo Research’s proposed strategy for the non-clinical development of hyaluronic acid-based medical devices for intra-articular viscosupplementation.
Paolo Baroldi Board member- Galileo Research Srl brought insights on intestinal microbiota, its potential uses and its classification from a regulatory perspective
“With this event dedicated to key players in the field,” said Mario Colombaro , CEO of Galileo Research Srl , “we intend to kick off a series of annual themed meetings and conferences focused on Galileo Research’s innovation and excellence for market evolution.”
So, we look forward to seeing you at the next edition of GAM.
